Definitive Healthcare Corp. Stock Price, News & Analysis

Definitive Healthcare (Nasdaq: DH) will report its Q4 and full year 2021 financial results on February 23, 2022, post-market close. The company will also host a conference call and webcast at 5:00 PM ET to discuss these results. Investors can access the live audio webcast via the Investor Relations website. A replay of the call will be available shortly after its conclusion and will remain accessible until March 9, 2022. Definitive Healthcare specializes in healthcare commercial intelligence, leveraging data and analytics for market success.

Definitive Healthcare (Nasdaq: DH) launched Latitude Discovery on January 25, 2022, aimed at aiding pre-commercial biopharma and medical device companies. This innovative tool allows users to perform iterative analyses of real-world data to evaluate market opportunities linked to therapy development. Latitude Discovery provides self-service access to extensive market intelligence, enabling efficient cohort creation and real-time commercial intelligence visualizations. This product is part of the Latitude Analytics Suite, enhancing companies' commercialization efforts with precise analytics.

Definitive Healthcare Corp. (Nasdaq: DH) has announced its inclusion in the Russell 1000® Index, effective from December 20, 2021. This milestone aims to enhance the company's visibility to investors and broaden its shareholder base. CEO Jason Krantz expressed optimism about this change, stating it enables the introduction of healthcare commercial intelligence to a wider audience, helping businesses succeed in the complex healthcare market.

Definitive Healthcare Corp. (Nasdaq: DH) announced that CEO Jason Krantz and CFO Rick Booth will present at the Barclays Virtual Global Technology, Media and Telecommunications Conference on December 7, 2021, at 9:45 a.m. Eastern Time. The live presentation will be accessible via the investor relations page of Definitive Healthcare's website, with a limited-time replay available afterward. Definitive Healthcare specializes in healthcare commercial intelligence, providing a SaaS platform to help clients identify market opportunities and drive commercial success.

Definitive Healthcare Corp. (Nasdaq: DH) has successfully closed its underwritten public offering of 11 million shares of Class A common stock at $36.00 per share. Underwriters hold a 30-day option for an additional 1.65 million shares. Proceeds will fund acquisitions and general corporate purposes, including buying 7 million limited liability interests from AIDH TopCo, LLC, and repurchasing 2.23 million shares of its Class A stock. Goldman Sachs and J.P. Morgan led the offering with support from Morgan Stanley and Barclays.

Definitive Healthcare Corp. (Nasdaq: DH) announced a public offering of 11 million shares of its Class A common stock at $36.00 per share. The offering includes a 30-day option for underwriters to purchase an additional 1.65 million shares. Closing is anticipated on November 22, 2021. Proceeds will fund acquisitions and general corporate purposes, such as buying 7 million limited liability interests from its subsidiary and repurchasing 2.23 million Class A shares. The offering is managed by Goldman Sachs & Co. and J.P. Morgan among others.

Definitive Healthcare Corp. (Nasdaq: DH) has initiated a public offering of 11,000,000 shares of its Class A common stock, with an option for underwriters to acquire an additional 1,650,000 shares. The net proceeds will fund acquisitions and general corporate purposes, including purchasing up to 7,000,000 limited liability interests from its subsidiary, AIDH TopCo, LLC, and repurchasing up to 2,233,238 shares of Class A stock. The offering is managed by leading financial firms, with a prospectus available through the SEC.

Definitive Healthcare Corp. (Nasdaq: DH) reported a strong Q3 2021, with revenue of $43.1 million, up 43% year-over-year. However, the company incurred a GAAP net loss of $(21.0) million, a significant rise from $(10.0) million in Q3 2020. Adjusted net income fell to $2.2 million compared to $5.1 million in the same quarter last year. The company forecasted Q4 2021 revenue between $44 million and $45 million, expecting a 32% year-over-year increase. Despite the losses, customer growth surged by 49%, reaching 377 clients with $100,000 or greater in annual recurring revenue.

Definitive Healthcare has integrated extensive Asian data sources into Monocl ExpertInsight, enhancing its platform with over 11 million worldwide expert profiles, focusing on the Chinese and Japanese healthcare markets. This expansion responds to customer demand for deeper insights in the APAC region, facilitating better expert identification and engagement strategies. The update includes local language capabilities, aiding medical professionals in understanding local experiences and exploring new scientific activities. This move aims to strengthen relationships and expand market presence in Asia-Pacific.